Couverture vaccinale avant et après instauration d’un traitement immunosuppresseur (y compris biothérapie) pour psoriasis

Nicolas, 2009, COL2-04 risque d’infections opportunistes (IO) sous traitement par anti-TNFα : résultats finaux des 3 ans de surveillance de l’observatoire RATIO, Med Mal Infect, 39, 2, 10.1016/S0399-077X(09)74269-6

Goëb, 2013, Conseils d’utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française, Rev Rhum, 80, 459, 10.1016/j.rhum.2013.08.004

Wine-Lee, 2013, From the Medical Board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis, J Am Acad Dermatol, 69, 1003, 10.1016/j.jaad.2013.06.046

Bello, 2012, Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents, Reumatismo, 64, 299, 10.4081/reumatismo.2012.299

Lebwohl, 2008, From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis, J Am Acad Dermatol, 58, 94, 10.1016/j.jaad.2007.08.030

Club rhumatismes et inflammations. Traitement anti-TNF alpha et suivi de la tolérance. Conduite à tenir en cas de vaccination. Rapport 2015. Disponible sur http://www.cri-net.com/recherche/fichesPratiques/Anti-TNF_Dec2010/F22_ANTI-TNF_VDEF.pdf.

Van Assen, 2011, EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 70, 414, 10.1136/ard.2010.137216

Rahier, 2014, Second European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohns Colitis, 8, 443, 10.1016/j.crohns.2013.12.013

Haut Conseil de la Santé publique. Vaccination des personnes immunodéprimées ou aspléniques. Recommandations. Rapport 2014. Disponible sur http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=322.

Institut de veille sanitaire. Couverture vaccinale. Données 2015. Disponible sur http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Couverture-vaccinale/Donnees/Grippe.

Guthmann, 2011, 21

Calendrier des vaccinations et recommandations vaccinales 2016. Rapport mars 2016. Disponible sur : http://social-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_2016.pdf.

Balato, 2009, Development of primary varicella infection during infliximab treatment for psoriasis, J Am Acad Dermatol, 60, 709, 10.1016/j.jaad.2008.10.002

Becart, 2008, Recurrent varicella in an adult psoriasis patient treated with etanercept, Dermatology, 217, 260, 10.1159/000149311

Choi, 2006, An atypical varicella exanthem associated with the use of infliximab, Int J Dermatol, 45, 999, 10.1111/j.1365-4632.2006.02779.x

Ito, 1991, Effects of tumor necrosis factor alpha on replication of varicella-zoster virus, Antiviral Res, 15, 183, 10.1016/0166-3542(91)90065-Y

Naganuma, 2013, Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD, Inflamm Bowel Dis, 19, 418, 10.1002/ibd.23027

Motaparthi, 2014, From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis, J Am Acad Dermatol, 70, 178, 10.1016/j.jaad.2013.08.049